Related Experiment Videos
[Heart failure and treatment of ventricular arrhythmias]
1Abteilung für Kardiologie, Universitätsspital Zürich.
Insights
Chronic heart failure (CHF) patients face high mortality. While some drugs manage CHF, antiarrhythmic drugs are generally not recommended, except for beta-blockers. Implantable defibrillators are preferred for life-threatening arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) presents a significant health burden with high annual mortality rates (15-50%).
- Current CHF pharmacotherapy includes vasodilators, diuretics, digoxin, and beta-blockers.
- Antiarrhythmic drugs are typically not recommended for CHF management, with beta-blockers being a notable exception due to their prognostic benefits.
Purpose:
- To review the current treatment landscape for chronic heart failure.
- To evaluate the role of antiarrhythmic drugs and implantable defibrillators in CHF management.
Summary:
- Amiodarone effectively suppresses ventricular arrhythmias but does not significantly impact overall mortality in CHF patients.
- Implantable cardioverter-defibrillators (ICDs) demonstrate superior efficacy over antiarrhythmic drug therapy in improving survival rates for sudden cardiac death survivors.
- ICDs are recommended as first-line therapy for patients experiencing life-threatening ventricular tachyarrhythmias.
Impact:
- Highlights the limited role of traditional antiarrhythmic drugs in CHF, emphasizing the need for alternative strategies.
- Establishes implantable defibrillators as a superior therapeutic option for preventing sudden cardiac death in high-risk CHF populations.
- Informs clinical decision-making regarding arrhythmia management in chronic heart failure patients, prioritizing life-saving interventions.
Abstract:
Chronic heart failure (CHF) is generally associated with a poor prognosis with an annual mortality rate ranging between 15-50% depending on the severity of cardiac dysfunction thus presenting a major health problem in our society. Drugs for the treatment of CHF include vasodilators (ACE-inhibitors, angiotensin II receptor blockers), diuretics, digoxin and beta-blockers. However, antiarrhythmic drugs are not currently recommended in the management of CHF with the exception of beta-blockers for which a favorable effect on the prognosis could be shown. Amiodarone is effective in the suppression of ventricular arrhythmias without a significant effect on total mortality. Implanted defibrillators are superior to antiarrhythmic drug therapy in prolonging survival among survivors of sudden cardiac death. They should be offered as firstline therapy in case of life-threatening ventricular tachy-arrhythmias.